Showing results (611-620 of 672) with videos related to
Sort By:
Pageof 68
Molecular & Cellular Proteomics : MCP|April 30, 2014
Realizing the promise of reverse phase protein arrays for clinical, translational, and basic research: a workshop report: the RPPA (Reverse Phase Protein Array) societyRehan Akbani, Karl-Friedrich Becker, Neil Carragher, et al.Hepatology (Baltimore, Md.)|October 24, 2006
Randomized controlled study of tenofovir and adefovir in chronic hepatitis B virus and HIV infection: ACTG A5127Marion G Peters, Janet Andersen, Patrick Lynch, et al.The Journal of Infectious Diseases|January 29, 2003
Interleukin-2 Increases CD4+ lymphocyte numbers but does not enhance responses to immunization: results of A5046sHernan Valdez, Ronald Mitsuyasu, Alan Landay, et al.Frontiers in Oncology|August 21, 2019
Digitoxin Inhibits Epithelial-to-Mesenchymal-Transition in Hereditary Castration Resistant Prostate CancerBette S Pollard, Mark A Suckow, William R Wolter, et al.The Journal of Infectious Diseases|October 6, 2005
Distinct mechanisms of T cell reconstitution can be identified by estimating thymic volume in adult HIV-1 diseaseRobert C Kalayjian, John Spritzler, Minya Pu, et al.Journal of Acquired Immune Deficiency Syndromes (1999)|April 21, 2004
Daily low-dose subcutaneous interleukin-2 added to single- or dual-nucleoside therapy in HIV infection does not protect against CD4+ T-cell decline or improve other indices of immune function: results of a randomized controlled clinical trial (ACTG 248)Mary A Vogler, Hedy Teppler, Rebecca Gelman, et al.Methods in Molecular Biology (Clifton, N.J.)|May 7, 2011
CFTR Folding Consortium: methods available for studies of CFTR folding and correctionKathryn W Peters, Tsukasa Okiyoneda, William E Balch, et al.Journal of Acquired Immune Deficiency Syndromes (1999)|October 31, 2013
Safety, tolerability, and immunogenicity of repeated doses of dermavir, a candidate therapeutic HIV vaccine, in HIV-infected patients receiving combination antiretroviral therapy: results of the ACTG 5176 trialBenigno Rodriguez, David M Asmuth, Roy M Matining, et al.Antiviral Research|October 23, 2004
A phase II, double-masked, randomized, placebo-controlled evaluation of a human monoclonal anti-Cytomegalovirus antibody (MSL-109) in combination with standard therapy versus standard therapy alone in the treatment of AIDS patients with Cytomegalovirus retinitisMichael J Borucki, John Spritzler, David M Asmuth, et al.Journal of Neurotrauma|December 31, 2010
Craniotomy: true sham for traumatic brain injury, or a sham of a sham?Jeffrey T Cole, Angela Yarnell, William S Kean, et al.Pageof 68